1
|
Mo Z, Gai S, Qin X, Meng D, Wu J, Ya W, Sun S, Huang Q. Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein. Int J Biol Macromol 2025; 301:140438. [PMID: 39880246 DOI: 10.1016/j.ijbiomac.2025.140438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2024] [Revised: 01/17/2025] [Accepted: 01/27/2025] [Indexed: 01/31/2025]
Abstract
The primary objective of this study was to conduct a comprehensive analysis of the mechanism by which TCF7 recombinant protein operates, as well as to examine its expression patterns within bladder cancer cells. This research seeks to establish a new theoretical framework and provide experimental data that could advance the field of molecular targeted therapy for bladder cancer. Erlotinib, a well-known targeted therapy drug, was administered to the bladder cancer cells, and we evaluated its antitumor effects through various assays such as cell proliferation, apoptosis, and cell cycle analysis. To delve deeper into the mechanisms of action associated with the TCF7 recombinant protein, we conducted extensive analyses of signaling pathways as well as gene expression profiles. The findings indicated a significant correlation between the expression levels of TCF7 in bladder cancer cells and the tumor's malignancy grade. Following the treatment with Erlotinib, we observed a marked inhibition of cell proliferation, an increase in apoptotic activity, and notable alterations in cell cycle distribution. The results suggested that the molecules of the TCF7 recombinant protein could potentially influence the biological characteristics and behavior of bladder cancer cells by modulating specific signaling pathways, particularly the Wnt/β-catenin signaling pathway. Further analysis of the gene expression profiles also enabled us to identify downstream target genes associated with TCF7, ultimately shedding light on its specific mechanisms of action in the context of bladder cancer.
Collapse
Affiliation(s)
- Zengmi Mo
- Department of Urology, The 923rd Hospital of Joint Logistics Support Force of the People's Liberation Army of China, Nanning 530022, China
| | - Shasha Gai
- Department of Urology, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise 533000, China
| | - Xiaopeng Qin
- Department of Urology, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise 533000, China
| | - Dongdong Meng
- Department of Urology, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise 533000, China
| | - Jichao Wu
- Department of Urology, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise 533000, China
| | - Wentong Ya
- Department of Urology, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise 533000, China
| | - Sheng Sun
- Department of Burn Plastic and Cosmetic Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, China
| | - Qun Huang
- Department of Urology, Affiliated Hospital of Youjiang Medical University for Nationalities and Key Laboratory of Molecular Pathology in Tumors of Baise, Baise 533000, China.
| |
Collapse
|
2
|
Lyu T, Wu K, Zhou Y, Kong T, Li L, Wang K, Fu P, Wei P, Chen M, Zheng J. Single-Cell RNA Sequencing Reveals the Tumor Heterogeneity and Immunosuppressive Microenvironment in Urothelial Carcinoma. Cancer Sci 2025; 116:710-723. [PMID: 39726326 PMCID: PMC11875766 DOI: 10.1111/cas.16436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2024] [Revised: 11/24/2024] [Accepted: 12/09/2024] [Indexed: 12/28/2024] Open
Abstract
Urothelial carcinoma (UC) can arise from either the lower urinary tract or the upper tract; they represent different disease entities and require different clinical treatment strategies. A full understanding of the cellular characteristics in UC may guide the development of novel therapies. Here, we performed single-cell transcriptome analysis from four patients with UC of the bladder (UCB), five patients with UC of the ureter (UCU), and four patients with UC of the renal pelvis (UCRP) to develop a comprehensive cell atlas of UC. We found the rare epithelial cell subtype EP9 with epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) features, and specifically expressed SOX6, which was associated with poor prognosis. We also found that ACKR1+ endothelial cells and inflammatory cancer-associated fibroblasts (iCAFs) were more enriched in UCU, which may promote pathogenesis. While ESM1+ endothelial cells may more actively participate in UCB and UCRP tumorigenesis by promoting angiogenesis. Additionally, CD8 + effector T cells were more enriched in UCU and UCRP patients, while Tregs were mainly enriched in UCB tumors. C1QC+ macrophages and LAMP3+ dendritic cells were more enriched in UCB, which is closely related to the formation of the heterogeneous immunosuppressive microenvironment. Furthermore, we found strong interactions between iCAFs, EP9, and Endo_ESM1, and different degrees of activation of the FGF-FGFR3 axis and immune checkpoint pathway were observed in different UC subtypes. Our study elucidated the cellular heterogeneity and the components of the microenvironment in UC arising from the upper and lower urinary tracts and provided novel therapeutic targets.
Collapse
Affiliation(s)
- Tianqi Lyu
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| | - Kerong Wu
- Department of Urology, Ningbo First HospitalSchool of Medicine Ningbo University, Zhejiang University Ningbo HospitalNingboChina
| | - Yincong Zhou
- Department of Bioinformatics, College of Life SciencesZhejiang UniversityHangzhouChina
| | - Tong Kong
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| | - Lin Li
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| | - Kaizhe Wang
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| | - Pan Fu
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| | - Pengyao Wei
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| | - Ming Chen
- Department of Bioinformatics, College of Life SciencesZhejiang UniversityHangzhouChina
| | - Jianping Zheng
- Cixi Institute of Biomedical Engineering, Chinese Academy of Science (CAS)Ningbo Institute of Materials Technology and Engineering, CAS NingboNingboChina
| |
Collapse
|
3
|
Leyderman M, Chandrasekar T, Grivas P, Li R, Bhat S, Basnet A, Shapiro O, Jacob J, Daneshvar MA, Kord E, Bratslavsky G, Goldberg H. Metastasis development in non-muscle-invasive bladder cancer. Nat Rev Urol 2024:10.1038/s41585-024-00963-y. [PMID: 39567681 DOI: 10.1038/s41585-024-00963-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/18/2024] [Indexed: 11/22/2024]
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer presentation and is characterized by a varying probability of recurrence and progression. Sporadically, patients with NMIBC might also develop tumour metastases without any pathological evidence of muscle-invasive disease within the bladder, a condition known as metastatic NMIBC. In the published literature, this phenomenon is limited to several case reports and small reviews, with few data regarding the possible aetiologies. Several possible factors can be potentially associated with metastatic NMIBC, including tumour understaging, the number of transurethral resection procedures received by the patient, the presence of circulating tumour cells, the modality used for diagnostic cystoscopy and possible gender-associated differences. In this Perspective, our aim was to integrate and report currently available data on this relatively rare entity and provide some potential aetiological explanations.
Collapse
Affiliation(s)
- Michael Leyderman
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
| | | | - Petros Grivas
- Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Roger Li
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Seetharam Bhat
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Alina Basnet
- Department of Medical Oncology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Oleg Shapiro
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
| | - Joseph Jacob
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
| | | | - Eyal Kord
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA
| | | | - Hanan Goldberg
- Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA.
- Upstate Urology at Mohawk Valley Health System (MVHS), Utica, NY, USA.
| |
Collapse
|
4
|
Nössing C, Herek P, Shariat SF, Berger W, Englinger B. Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine. Curr Opin Urol 2024; 34:251-257. [PMID: 38602053 PMCID: PMC11155291 DOI: 10.1097/mou.0000000000001177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/12/2024]
Abstract
PURPOSE OF REVIEW Bladder cancer incidence is on the rise, and until recently, there has been little to no change in treatment regimens over the last 40 years. Hence, it is imperative to work on strategies and approaches to untangle the complexity of intra- and inter-tumour heterogeneity of bladder cancer with the aim of improving patient-specific care and treatment outcomes. The focus of this review is therefore to highlight novel targets, advances, and therapy approaches for bladder cancer patients. RECENT FINDINGS The success of combining an antibody-drug conjugate (ADC) with immunotherapy has been recently hailed as a game changer in treating bladder cancer patients. Hence, interest in other ADCs as a treatment option is also rife. Furthermore, strategies to overcome chemoresistance to standard therapy have been described recently. In addition, other studies showed that targeting genomic alterations (e.g. mutations in FGFR3 , DNA damage repair genes and loss of the Y chromosome) could also be helpful as prognostic and treatment stratification biomarkers. The use of single-cell RNA sequencing approaches has allowed better characterisation of the tumour microenvironment and subsequent identification of novel targets. Functional precision medicine could be another avenue to improve and guide personalized treatment options. SUMMARY Several novel preclinical targets and treatment options have been described recently. The validation of these advances will lead to the development and implementation of robust personalized treatment regimens for bladder cancer patients.
Collapse
Affiliation(s)
| | - Paula Herek
- Department of Urology, Comprehensive Cancer Center
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria
| | - Shahrokh F. Shariat
- Department of Urology, Comprehensive Cancer Center
- Department of Urology, Weill Cornell Medical College, New York, New York
- Department of Urology, University of Texas Southwestern, Dallas, Texas, USA
- Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- Institute for Urology, University of Jordan, Amman, Jordan
- Research center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
- Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
| | - Walter Berger
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria
| | - Bernhard Englinger
- Department of Urology, Comprehensive Cancer Center
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria
| |
Collapse
|
5
|
Rabadi I, Carpentieri D, Wang J, Zenhausern F, Gu J. On reactive Ion Etching of Parylene-C with Simple Photoresist Mask for Fabrication of High Porosity Membranes to Capture Circulating and Exfoliated Tumor Cells. MICROMACHINES 2024; 15:521. [PMID: 38675332 PMCID: PMC11051955 DOI: 10.3390/mi15040521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 04/09/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024]
Abstract
A high porosity micropore arrayed parylene membrane is a promising device that is used to capture circulating and exfoliated tumor cells (CTCs and ETCs) for liquid biopsy applications. However, its fabrication still requires either expensive equipment or an expensive process. Here, we report on the fabrication of high porosity (>40%) micropore arrayed parylene membranes through a simple reactive ion etching (RIE) that uses photoresist as the etching mask. Vertical sidewalls were observed in etched parylene pores despite the sloped photoresist mask sidewalls, which was found to be due to the simultaneous high DC-bias RIE induced photoresist melting and substrate pedestal formation. A theoretical model has been derived to illustrate the dependence of the maximum membrane thickness on the final pore-to-pore spacing, and it is consistent with the experimental data. A simple, yet accurate, low number (<50) cell counting method was demonstrated through counting cells directly inside a pipette tip under phase-contrast microscope. Membranes as thin as 3 μm showed utility for low number tumor cell capture, with an efficiency of 87-92%.
Collapse
Affiliation(s)
- Inad Rabadi
- Center for Applied NanoBioscience and Medicine, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA; (I.R.); (F.Z.)
- Department of Basic Medical Sciences, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA
| | | | - Jue Wang
- Dignity Health-Cancer Institute at St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85004, USA;
| | - Frederic Zenhausern
- Center for Applied NanoBioscience and Medicine, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA; (I.R.); (F.Z.)
- Department of Basic Medical Sciences, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA
- Honor Health Research Institute, Scottsdale, AZ 85258, USA
| | - Jian Gu
- Center for Applied NanoBioscience and Medicine, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA; (I.R.); (F.Z.)
- Department of Basic Medical Sciences, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA
| |
Collapse
|
6
|
Ren L, Huang D, Liu H, Ning L, Cai P, Yu X, Zhang Y, Luo N, Lin H, Su J, Zhang Y. Applications of single‑cell omics and spatial transcriptomics technologies in gastric cancer (Review). Oncol Lett 2024; 27:152. [PMID: 38406595 PMCID: PMC10885005 DOI: 10.3892/ol.2024.14285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 01/19/2024] [Indexed: 02/27/2024] Open
Abstract
Gastric cancer (GC) is a prominent contributor to global cancer-related mortalities, and a deeper understanding of its molecular characteristics and tumor heterogeneity is required. Single-cell omics and spatial transcriptomics (ST) technologies have revolutionized cancer research by enabling the exploration of cellular heterogeneity and molecular landscapes at the single-cell level. In the present review, an overview of the advancements in single-cell omics and ST technologies and their applications in GC research is provided. Firstly, multiple single-cell omics and ST methods are discussed, highlighting their ability to offer unique insights into gene expression, genetic alterations, epigenomic modifications, protein expression patterns and cellular location in tissues. Furthermore, a summary is provided of key findings from previous research on single-cell omics and ST methods used in GC, which have provided valuable insights into genetic alterations, tumor diagnosis and prognosis, tumor microenvironment analysis, and treatment response. In summary, the application of single-cell omics and ST technologies has revealed the levels of cellular heterogeneity and the molecular characteristics of GC, and holds promise for improving diagnostics, personalized treatments and patient outcomes in GC.
Collapse
Affiliation(s)
- Liping Ren
- School of Healthcare Technology, Chengdu Neusoft University, Chengdu, Sichuan 611844, P.R. China
| | - Danni Huang
- Department of Radiology, Central South University Xiangya School of Medicine Affiliated Haikou People's Hospital, Haikou, Hainan 570208, P.R. China
| | - Hongjiang Liu
- School of Computer Science and Technology, Aba Teachers College, Aba, Sichuan 624099, P.R. China
| | - Lin Ning
- School of Healthcare Technology, Chengdu Neusoft University, Chengdu, Sichuan 611844, P.R. China
| | - Peiling Cai
- School of Basic Medical Sciences, Chengdu University, Chengdu, Sichuan 610106, P.R. China
| | - Xiaolong Yu
- Hainan Yazhou Bay Seed Laboratory, Sanya Nanfan Research Institute, Material Science and Engineering Institute of Hainan University, Sanya, Hainan 572025, P.R. China
| | - Yang Zhang
- Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China
| | - Nanchao Luo
- School of Computer Science and Technology, Aba Teachers College, Aba, Sichuan 624099, P.R. China
| | - Hao Lin
- Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu, Sichuan 611731, P.R. China
| | - Jinsong Su
- Research Institute of Integrated Traditional Chinese Medicine and Western Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China
| | - Yinghui Zhang
- School of Healthcare Technology, Chengdu Neusoft University, Chengdu, Sichuan 611844, P.R. China
| |
Collapse
|
7
|
Myoen S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, Shindo N, Yamaguchi K, Yasuda J, Abe J, Imai T, Sato I, Adachi H, Kawamura S, Ito A, Tamai K. CD271 promotes proliferation and migration in bladder cancer. Genes Cells 2024; 29:73-85. [PMID: 38016691 DOI: 10.1111/gtc.13087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 11/08/2023] [Accepted: 11/15/2023] [Indexed: 11/30/2023]
Abstract
Bladder cancer is a urothelial cancer and effective therapeutic strategies for its advanced stages are limited. Here, we report that CD271, a neurotrophin receptor, promotes the proliferation and migration of bladder cancer cells. CD271 knockdown decreased proliferation in both adherent and spheroid cultures, and vice versa when CD271 was overexpressed in bladder cancer cell lines. CD271 depletion impaired tumorigenicity in vivo. Migration activity was reduced by CD271 knockdown and TAT-Pep5, a known CD271-Rho GDI-binding inhibitor. Apoptosis was induced by CD271 knockdown. Comprehensive gene expression analysis revealed alterations in E2F- and Myc-related pathways upon CD271 expression. In clinical cases, patients with high CD271 expression showed significantly shortened overall survival. In surgically resected specimens, pERK, a known player in proliferation signaling, colocalizes with CD271. These data indicate that CD271 is involved in bladder cancer malignancy by promoting cell proliferation and migration, resulting in poor prognosis.
Collapse
Affiliation(s)
- Shingo Myoen
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
- Division of Urology, Miyagi Cancer Center, Natori, Miyagi, Japan
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Mai Mochizuki
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| | - Rie Shibuya-Takahashi
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| | - Haruna Fujimori
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| | - Norihisa Shindo
- Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| | - Kazunori Yamaguchi
- Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| | - Jun Yasuda
- Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| | - Jiro Abe
- Division of Thoracic Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan
| | - Takayuki Imai
- Division of Head and Neck Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan
| | - Ikuro Sato
- Division of Pathology, Miyagi Cancer Center, Natori, Miyagi, Japan
| | - Hisanobu Adachi
- Division of Urology, Miyagi Cancer Center, Natori, Miyagi, Japan
| | | | - Akihiro Ito
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Keiichi Tamai
- Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan
| |
Collapse
|
8
|
Gonzales LISA, Qiao JW, Buffier AW, Rogers LJ, Suchowerska N, McKenzie DR, Kwan AH. An omics approach to delineating the molecular mechanisms that underlie the biological effects of physical plasma. BIOPHYSICS REVIEWS 2023; 4:011312. [PMID: 38510160 PMCID: PMC10903421 DOI: 10.1063/5.0089831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 02/24/2023] [Indexed: 03/22/2024]
Abstract
The use of physical plasma to treat cancer is an emerging field, and interest in its applications in oncology is increasing rapidly. Physical plasma can be used directly by aiming the plasma jet onto cells or tissue, or indirectly, where a plasma-treated solution is applied. A key scientific question is the mechanism by which physical plasma achieves selective killing of cancer over normal cells. Many studies have focused on specific pathways and mechanisms, such as apoptosis and oxidative stress, and the role of redox biology. However, over the past two decades, there has been a rise in omics, the systematic analysis of entire collections of molecules in a biological entity, enabling the discovery of the so-called "unknown unknowns." For example, transcriptomics, epigenomics, proteomics, and metabolomics have helped to uncover molecular mechanisms behind the action of physical plasma, revealing critical pathways beyond those traditionally associated with cancer treatments. This review showcases a selection of omics and then summarizes the insights gained from these studies toward understanding the biological pathways and molecular mechanisms implicated in physical plasma treatment. Omics studies have revealed how reactive species generated by plasma treatment preferentially affect several critical cellular pathways in cancer cells, resulting in epigenetic, transcriptional, and post-translational changes that promote cell death. Finally, this review considers the outlook for omics in uncovering both synergies and antagonisms with other common cancer therapies, as well as in overcoming challenges in the clinical translation of physical plasma.
Collapse
Affiliation(s)
- Lou I. S. A. Gonzales
- School of Life and Environmental Sciences, The University of Sydney, NSW 2006, Australia
| | - Jessica W. Qiao
- School of Life and Environmental Sciences, The University of Sydney, NSW 2006, Australia
| | - Aston W. Buffier
- School of Life and Environmental Sciences, The University of Sydney, NSW 2006, Australia
| | | | | | | | - Ann H. Kwan
- Author to whom correspondence should be addressed:
| |
Collapse
|
9
|
Bordeleau F, Brownell D, Chabaud S, Huot ME, Bolduc S. Recreating heterogeneity of bladder cancer microenvironment to study its recurrences and progression. Stem Cell Investig 2023; 10:5. [PMID: 36909249 PMCID: PMC9995704 DOI: 10.21037/sci-2023-004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 02/07/2023] [Indexed: 03/09/2023]
Affiliation(s)
- François Bordeleau
- CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC, Canada.,Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Quebec City, QC, Canada
| | - David Brownell
- CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC, Canada.,Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC, Canada
| | - Stephane Chabaud
- CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC, Canada.,Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC, Canada
| | - Marc-Etienne Huot
- CHU de Québec-Université Laval Research Center (Oncology Division) and Université Laval Cancer Research Center, Quebec City, QC, Canada.,Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Quebec City, QC, Canada
| | - Stephane Bolduc
- CHU de Québec-Université Laval Research Center (Regenerative Medicine Division), Quebec City, QC, Canada.,Centre de Recherche en Organogénèse Expérimentale/LOEX, Université Laval, Quebec City, QC, Canada.,Department of Surgery, Université Laval, Quebec City, QC, Canada
| |
Collapse
|